After the traumatic events of the last few years, some of your clients may be experiencing a crisis of confidence in our economic system, institutions and leaders.
Biotech/Health Care: Growth Drivers
John T. Boris Citigroup Global Markets email@example.com 212-816-1635 The U.S. major pharmaceutical group is trading at 8.3x (times) 2011 estimated earnings per share (EPS), representing a 32 percent discount...
Have you noticed that as the baby boom generation ages, the advertising we see on television changes along with them? Think back to those golden...
Taxes are, for a change, probably the easiest area to consider when assessing the implications of healthcare reform for advisors and their clients. To be...
What's Next for Health Care?
The health care sector has never seen anything like this and neither has the American public. After months of political wrangling, the Affordable Health Care for...
The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform
Powered by Standard & Poor's MarketScope Advisor While the inability of Congress to form a consensus on how to change the current healthcare system seems to...
SEC Targets UBS Banker in Case of Insider Trading
Also, the U.S. Attorney's office in New York filed criminal charges against Igor Poteroba, a healthcare banker in the Swiss bank's New York office, and his friend, Aleksey Koval.
Health Care: Potent Pipelines
Damien Conover, CFA Karen Andersen, CFA Morningstar 312-696-6000 Pharmaceuticals: While the majority of pharmaceutical companies are losing patents on major blockbuster drugs over the next five years, strong pipelines...
High Hopes and Altered Genes
Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...
The Right Remedies
Research's Health Care Guide: Beckman Coulter Inc. (BEC) Roche Holding AG (RHHBY) Watson Pharmaceuticals Inc. (WPI) --- Karen Andersen,...